everytihng about Coluracetam

CAS No:135463-81-9 Purity:99% Appearance:white crystalline powder Package:1kg/bag. (formerly known as MKC-231) was initially developed and tested by the

Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the

drug failed to reach endpoints in its clinical trials it was in-licensed by

BrainCells Inc for investigations into major depression disorder (MDD),

after being awarded a "Qualifying Therapeutic Discovery Program Grant" by

the state of California.Findings from its Phase 2a clinical trials have

suggested that it would be an ideal medication for co-morbid MDD with

generalized anxiety disorder (GAD).BrainCells Inc is currently out-

licensing the drug for this purpose.It may also have potential use in

prevention and treatment of ischemic retinopathy and retinal and optic

nerve injury. Coluracetam enhances high-affinity choline uptake (HACU) which is the

rate-limiting step of acetylcholine (ACh) synthesis, and is the only known

choline uptake enhancer to currently exist. Studies have shown Coluracetam

to improve learning impairment on a single oral dose given to rats which

have been exposed to cholinergic neurotoxins. Subsequent studies have shown

that it may induce long-lasting procognitive effects by changing the

choline transporter regulation system.